Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer

Cancer Science

Volumn 103, Issue 8, 2012, Pages 1508-1512

  Niikura, Naoki ^a   Iwamoto, Takayuki ^b   Masuda, Shinobu ^c   Kumaki, Nobue ^a   Xiaoyan, Tang ^c   Shirane, Masatoshi ^d   Mori, Kazushige ^d   Tsuda, Banri ^a   Okamura, Takuho ^a   Saito, Yuki ^a   Suzuki, Yasuhiro ^a   Tokuda, Yutaka ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Product Research   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN;

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENOMICS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MITOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84864310664     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02319.x     Document Type: Article

References (23)

1. Dowsett M, Nielsen TO, A'Hern R et al. Assessment of Ki67 in Breast Cancer: recommendations from the International Ki67 in Breast Cancer Working Group. JNCI: J Natl Cancer Inst 2011; 103: 1656-64.
2. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-47.
3. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-312.
4. Cuzick J, Dowsett M, Pineda S et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 2011; 29: 4273-8.
5. Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-50.
6. Hugh J, Hanson J, Cheang MCU et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an Immunohistochemical Definition in the BCIRG 001 Trial. J Clin Oncol 2009; 27: 1168-76.
7. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-74.
8. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
9. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26.
10. Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671-9.
11. Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98: 262-72.
12. Buyse M, Loi S, van't Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98: 1183-92.
13. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360: 790-800.
14. Wirapati P, Sotiriou C, Kunkel S et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10: R65.
15. Iwamoto T, Lee JS, Bianchini G et al. First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. Breast Cancer Res Treat 2011; 130: 155-64.
16. The World Health Organization. Histological typing of breast tumors. Neoplasma 1983; 30: 113-23.
17. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.
18. Umemura S, Shirane M, Takekoshi S et al. Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome. Br J Cancer 2009; 100: 764-71.
19. Bianchini G, Iwamoto T, Qi Y et al. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. Cancer Res 2010; 70: 8852-62.
20. de Azambuja E, Cardoso F, de Castro G et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12155 patients. Br J Cancer 2007; 96: 1504-13.
21. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32, 825 patients. Breast 2008; 17: 323-34.
22. Williams DJ, Cohen C, Darrow M et al. Proliferation (Ki-67 and phosphohistone H3) and oncotype DX recurrence score in estrogen receptor-positive breast cancer. Appl Immunohistochem Mol Morphol 2011; 19: 431-6.
23. Yerushalmi R, Woods R, Ravdin PM et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11: 174-83.